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Aberrant Fatty Acid-Binding Protein-7 Gene
Expression in Cutaneous Malignant Melanoma
Yasufumi Goto1, Kazuo Koyanagi1, Norihiko Narita1, Yutaka Kawakami2, Minoru Takata3, Aya Uchiyama3,
Linhda Nguyen1, Tung Nguyen1, Xing Ye4, Donald L. Morton5 and Dave S.B. Hoon1
Fatty acid-binding protein-7 (FABP7) has been shown to be expressed in cutaneous melanoma; however, its role
in tumor progression is unclear. Expression of FABP7 was assessed during melanoma progression through
assessment of various clinicopathology stages of primary tumor progression and metastasis. FABP7 mRNA was
highly expressed in 60 of 87 (69%) primary melanomas, compared with significant (Po0.0001) reduction in 13 of
68 (19%) metastatic melanomas. Analysis of 37 paired primary and metastatic melanomas by immunohis-
tochemistry with anti-FABP7 Ab showed 73 and 27% positivity, respectively (Po0.001). FABP7 detection of
metastatic tissues was inversely correlated with relapse-free (Po0.0001) and overall (Po0.0001) survival. To
examine FABP7 expression loss in advanced melanomas, loss of heterozygosity (LOH) was assessed using
microsatellite markers encompassing the FABP7 gene. LOH was identified in 10 of 20 (50%) metastatic
melanomas at 6q22.31, compared with 0 of 14 primary melanomas (P¼ 0.0017). FABP7 as a surrogate biomarker
for circulating tumor cells (CTCs) in the blood was assessed by quantitative real-time (qRT)–PCR from melanoma
patients’ blood (n¼ 134). Assessment of patients’ blood showed that FABP7(þ ) CTC decreased with disease
progression. FABP7 may function as a tumor progression gene and can be used as a potential diagnostic
biomarker of early-stage melanoma systemic spreading in blood.
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INTRODUCTION
Melanoma remains primarily a surgically treated disease that
does not respond well to currently available systemic
therapies, whereas early detection and diagnosis can
significantly improve disease management and outcome
(Morton et al., 2006). Better prognostic biomarkers of early-
stage melanoma are needed to identify the potential of
primary tumors to metastasize. Fatty acid-binding protein-7
(FABP7), also known as B-FABP (brain-type fatty acid-binding
protein), and BLBP (brain lipid-binding protein) are involved
in intracellular long-chain fatty acid transport (Sweetser et al.,
1987; Feng et al., 1994; Kurtz et al., 1994; Shi et al., 1997).
Originally identified in the mammalian brain, FABP7 has
been linked to several cell-differentiation pathways that lead
to the inhibition of cell proliferation and tissue differentiation
(Anthony et al., 2005; Arai et al., 2005). FABP expression in
tissues has been related to lipid-metabolizing capacity
associated with fatty acids (Haunerland and Spener, 2004).
There are several FABP family members, of which all are
characterized by a b-barrel structure, membrane activity, and
specific ligand-binding selectivity.
In cancer, FABP7 has been identified in glioblastoma
(Liang et al., 2005), renal cell carcinoma (Domoto et al.,
2007), and melanomas (de Wit et al., 2005; Goto et al.,
2006). It has been shown that expression of FABP7 is
correlated with survival in patients with glioblastoma (Liang
et al., 2005), whereas FABP7 has also been shown to inhibit
tumor growth of a breast cancer cell when overexpressed (Shi
et al., 1997; Haunerland and Spener, 2004). However the
role of FABP7 in tumor progression still remains unclear. In a
recent study, FABP7 was identified as one of a panel of genes
in the oligonucleotide arrays that appeared to be differentially
expressed between nevus and metastatic melanoma in a
small sample size study (de Wit et al., 2005).
We recently showed, by mRNA and western blot analysis,
frequent expression of FABP7 in human metastatic melanoma
cell lines and tissues as compared with various normal
tissues. In addition, FABP7 was shown to be involved in
proliferation and invasion of melanoma cells in vitro (Goto
et al., 2006). The primary objective of this study was to
determine FABP7 expression during melanoma progression,
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by assessing the expression of FABP7 mRNA in a large
sample size of primary and metastatic melanomas of different
American Joint Committee on Cancer (AJCC) stages. The
secondary objective was to determine the association
of FABP7 expression with survival of melanoma patients.
Our group has previously shown the prognostic utility of
tumor mRNA biomarkers in detecting and monitoring
circulating tumor cells (CTCs) in the blood of patients with
melanoma (Koyanagi et al., 2005a). FABP7 utility as a
potential surrogate biomarker of CTCs in patients’ blood
comparing early and advanced stage melanoma was
assessed.
RESULTS
FABP7 expression in tumors
FABP7 mRNA expression was assessed by an optimized
quantitative real-time RT–PCR (qRT) assay in 155 cutaneous
melanomas and 13 normal skin tissue. In the assessment of
155 melanoma specimens, the absolute mRNA copies of
FABP7 ranged from 0 to 9.01102. Receiver operating
characteristic curve analysis was conducted to evaluate
the diagnostic accuracy of FABP7 for the binary outcome
(87 primary melanoma vs 13 normal skin tissue). The area
under the receiver operating characteristic curve± SEM was
0.824±0.032 (Figure 1).
To determine the pattern of FABP7 expression relative to
early tumor progression, we examined the primary melano-
mas of specific AJCC stages of disease. FABP7 mRNA was
detected in 20 of 30 (67%) AJCC stage I primary cutaneous
melanomas, 17 of 25 (68%) AJCC stage II primary melano-
mas, and 23 of 32 (72%) AJCC stage III primary melanomas.
These analyses showed that there was no significant
differences in FABP7 expression in primary lesions regardless
of the clinical stage. However, in advanced metastatic
lesions, FABP7 was present only in 13 of 68 (19%) AJCC
stage III and IV metastatic melanomas. The level of FABP7
mRNA expression was significantly higher in primary
melanomas than in metastatic melanomas and in normal
skin tissues (Po0.0001, Po0.0001, respectively, Figure 2).
This indicated a decrease in FABP7 expression during tumor
progression from primary to metastatic lesions, which
suggested a significant downregulation of FABP7 in advanced
stage metastatic melanomas.
By immunohistochemistry (IHC) assessment, the expres-
sion of FABP7 protein using 37 paired tissues of primary and
metastatic melanomas was analyzed. FABP7 protein was
detected in 27 of 37 (73%) primary melanomas, whereas
FABP7 was present only in 10 of 37 (27%) metastatic
melanomas (Po0.0001; Supplementary Figure 1). Interest-
ingly, the expression of FABP7 from 17 metastatic melanoma
patients was lost, although paired primary melanomas from
the same patients expressed FABP7 protein. This analysis
further verified a decrease in FABP7 expression during tumor
progression from primary to metastatic lesions.
Correlation of FABP7 expression with disease outcome
To assess whether FABP7 expression loss is a tumor
progression prognostic biomarker, the correlation of FABP7
expression in metastatic tissues with relapse-free survival and
overall survival in melanoma patients was assessed. Thirty-
nine metastatic melanomas (19 AJCC stage III and 20 AJCC
stage IV) were used for analyses of FABP7 expression
correlation with disease relapse and overall survival. In the
stage III group, there were 3 stage IIIa, 12 stage IIIb, and
4 stage IIIc. A median follow-up time was 31 months in all
the patients. There were 4 of 19 (21%) stage III and 4 of 20
(20%) stage IV patients who expressed FABP7.
FABP7 detection was inversely correlated with relapse-
free survival (Po0.0001; Figure 3a). There were 61 and 21%
patients whose tumors did not express FABP7 and who were
relapse free for 12 months and 60 months, respectively, and
whose median relapse-free survival was 23.0 months
(95% confidence interval (CI) 12.0–58.0). No patient with
FABP7 positive survived relapse-free for 12 months, and
the median survival months was 4.0 (95% CI 2.0–8.0).
Univariate analysis also showed that pT stage (P¼ 0.014), M
classification (Po0.0001), and AJCC stage (P¼0.013) were
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Figure 1. Receiver operating characteristic of FABP7 in primary melanoma.
The AUC of FABP7 is 0.824 (Po0.0001).
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Figure 2. Ratio of the FABP7/GAPDH mRNA copies in melanoma lines and
tissues. The cutoff point (dotted line) for FABP7 positivity was set at 0.0011
(the mean ratio of the FABP7/GAPDH mRNA copies plus 3 SD of normal
human skin controls). Horizontal bars denote mean mRNA copies and SEM.
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significantly correlated with relapse-free survival (Table 1A).
Multivariate analysis showed that tumor FABP7 expression
was a significant predictor for disease relapse (risk ratio, 6.47;
95% CI 2.47–16.96; P¼ 0.0001) as well as AJCC stage (risk
ratio, 2.82; 95% CI 1.31–6.07; P¼ 0.0079, Table 1B).
Moreover FABP7 expression was inversely correlated with
overall survival (Po0.0001; Figure 3b). There were 87 and
43% patients whose tumors did not express FABP7 survived
for 12 and 60 months, respectively, and whose median
survival was 40.0 months (95% CI 24.0–103.0), whereas
there were 38 and 0% patients with positive FABP7 who
survived for 12 and 60 months, respectively, and whose
median months of survival was 9.5 (95% CI 8.0–13.0).
Univariate analysis also showed that N classification
(P¼0.0096), M classification (Po0.0001), and AJCC stage
(P¼0.0008) were significantly correlated with overall survi-
val (Table 1A). Multivariate analysis showed that FABP7
detection (risk ratio, 14.52; 95% CI 4.38–40.09; Po0.0001)
was a significant independent prognostic factor for overall
survival as well as AJCC stage (risk ratio, 4.78; 95% CI
1.96–11.66; P¼ 0.0006).
FABP7 locus genomic aberration
To determine genomic deletion as the mechanism of the
downregulation of FABP7 expression in metastatic melano-
ma, loss of heterozygosity (LOH) was assessed in the 6q21–23
chromosomal region that includes the FABP7 gene locus.
Melanoma lines and Paraffin-embedded archival tissue
(PEAT) tumor specimens were assessed for three defined
microsatellite markers encompassing the FABP7 gene locus
(Figure 4).
Nine cell lines established from metastatic melanomas
were used for analysis (Table 2A). In four of nine cell lines
(44%), LOH in the FABP7 gene region was identified in all
three microsatellite markers; in one line, FABP7 LOH was
identified in two of the three microsatellite markers.
Interestingly, FABP7 mRNA expression detected by qRT
was highly suppressed in four of five LOH cell lines, whereas
FABP7 mRNA was expressed in three of four R cell lines
(Figure 5) (Supplementary Figure 2). The inverse correlation
between FABP7 LOH and mRNA expression suggested that
deletion or genomic instability of the FABP7 locus during
metastatic progression is a potential factor for loss or
downregulation of the FABP7 gene. Cell line IHC analysis
of FABP7 expression was concordant with LOH results
except for one cell line.
To confirm the LOH of the 6q21–23 observation in the cell
lines, we assessed melanoma tumor tissues. We investigated
LOH of the FABP7 region in 14 PEAT primary melanomas. As
shown in Table 2B, FABP7 LOH frequency at individual
microsatellite markers D6S268, D6S1702, and D6S262 was
14, 0, and 0%, respectively. By contrast, in 20 PEAT
specimens from metastatic melanomas, the frequency of
FABP7 LOH at D6S268, D6S1702, and D6S262 was 60, 50,
and 50%, respectively (Table 2C); at least two of the three
microsatellite markers were positive in 10 (50%) of these
specimens. LOH was identified in 10 of 20 (50%) metastatic
melanomas at 6q22.31, compared with 0 of 14 primary
melanomas. The frequency of the 6q21–23 region LOH was
significantly higher in metastatic melanomas than in primary
melanomas (P¼0.0017).
Other potential mechanisms of downregulation of FABP7
could be because of methylation of the FABP7 promoter
region. However, CpG islands of the FABP7 promoter region
have not been reported, and in the evaluation of the promoter
region near the FABP7 gene open-reading frame, no obvious
CpG islands were found.
FABP7 mRNA detection in blood as a surrogate CTC biomarker
We examined FABP7 expression as a surrogate mRNA
biomarker for CTCs in cells in the blood of melanoma
patients. An optimal direct CTC qRT assay for FABP7
detection was established using blood from melanoma
patients and normal healthy donors. The direct CTC qRT
assay in melanoma has been used for other melanoma CTC
biomarkers (Koyanagi et al., 2005b). Normal donor periph-
eral blood lymphocytes (PBLs) were shown to be negative for
the optimal FABP7 qRT assay. A melanoma cell spiking
experiment, performed to assess qRT assay sensitivity,
showed a direct correlation between absolute FABP7 mRNA
copies and the number of melanoma cells added to normal
PBLs (Figure 6). FABP7 mRNA was positive for 10 melanoma
cells mixed with 107 PBLs in three separate experiments.
These studies indicated the feasibility and sensitivity of the
FABP7 qRT assay to detect CTCs in blood.
FABP7 mRNA was measured by an optimized qRT assay in
134 blood specimens from melanoma patients of different
AJCC stages, and 93 blood specimens from healthy donors
(Figure 7). Absolute mRNA copies of FABP7 in melanoma
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Figure 3. FABP7 mRNA expression in metastatic tumors related to disease
outcome. Kaplan–Meier estimates of relapse-free survival (a) and overall
survival (b) based on FABP7 mRNA detection in melanoma metastases.
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Table 1A. Univariate analysis of clinical factors for
prediction of relapse-free survival and overall survival
Relapse-free survival Overall survival
Factors Patients Number Log-rank Number Log-rank
Gender
Male 23 18 0.77 17 0.37
Female 16 12 9
Age (years)
p50 18 15 0.84 13 0.92
450 21 15 13
Primary site
Extremity 15 11 0.77 8 0.40
Head/neck 6 5 5
Trunk 12 9 8
Unknown 6 5 5
pT stage
pT1 8 8 0.014 6 0.20
pT2 8 2 2
pT3 7 6 6
pT4 10 9 7
pTO 6 5 5
Clark level
3 8 6 0.65 5 0.97
4 17 12 11
5 8 7 5
Unknown 6 5 5
N classification
N0 7 6 0.094 6 0.0096
N1 18 11 7
N2 10 9 9
N3 4 4 4
M Classification
M0 19 11 o0.0001 7 o0.0001
M1a 14 13 13
M1b 5 5 5
M1c 1 1 1
AJCC stage
Stage 3m 19 11 0.013 7 0.0008
Stage 4m 20 19 19
Table 1A. Continued
Relapse-free survival Overall survival
Factors Patients Number Log-rank Number Log-rank
Expression of FABP7
Positive 8 8 o0.0001 8 o0.0001
Negative 31 22 18
Table 1B. Multivariate analysis for disease outcome
Relapse-free survival Overall survival
Factor P-value
Hazard ratio
(95% CI) P-value
Hazard ratio
(95% CI)
AJCC stage 0.0079 2.82 (1.31, 6.07) 0.0006 4.782 (1.96, 11.66)
FABP7 0.0001 6.47 (2.47, 16.96) o0.0001 14.52 (4.38, 48.09)
CI, confidence interval.
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Figure 4. Location of FABP7 gene and the three microsatellite markers used
for LOH assessment on chromosome 6. FABP7 gene is located at 6q22.31,
between D6S268 and D6S1702.
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patients’ blood varied in levels, and in healthy donors there
was no detection of FABP7 mRNA.
To determine the potential of FABP7 expression as a
surrogate CTC biomarker of early-stage disease, blood was
assessed from different AJCC stage melanoma patients.
FABP7 was positive in blood from 17 of 72 (24%) patients
with stage I/II disease, 11 of 34 (32%) patients with stage III
disease, and 6 of 28 (21%) patients with stage IV disease.
Stage I/II, stage III, or stage IV were significantly (Po0.001)
greater than normal donor blood (0 of 93), respectively. As
expected, CTC detection in advanced stage melanoma blood
did not increase likely due to the loss of FABP7 gene
expression. Previously, we have shown CTC detection by
known melanoma biomarkers in advanced stage mela-
noma blood to increase significantly to early-stage disease
(Koyanagi et al., 2005a, b). CTC detection in early-stage
disease was less frequent, as expected, since metastasis is less
frequent. However, early-stage melanomas (stage II/III) after
primary tumor removal can reoccur as systemic metastases
within 10 years of follow-up (Balch et al., 2001).
Table 2A. FABP7 LOH status in metastatic melanoma
lines
Microsatellite markers
Cell lines D6S268 D6S1072 D6S262
ME-25 R R R
ME-26 LOH LOH LOH
ME-27 R R R
ME-28 R R R
ME-29 LOH LOH R
ME-30 R R R
ME-31 LOH LOH LOH
ME-32 LOH LOH LOH
ME-33 LOH LOH LOH
LOH, loss of heterozygosity; R, retention of alleles.
Table 2B. LOH status in primary melanomas
Microsatellite markers
Patient Stage D6S268 D6S1072 D6S262 LOH
1 I R R R N
2 I R R R N
3 I R R R N
4 I R R R N
5 I R R R N
6 I R R R N
7 II R R R N
8 II LOH R R Y
9 II R R R N
10 II R R R N
11 II R R R N
12 II LOH R R Y
13 III R R R N
14 III R R R N
LOH, loss of heterozygosity; R, retention of alleles.
LOH inpatient tumor: N, no; Y, yes.
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Figure 5. FABP7 mRNA expression, LOH status, IHC analysis of melanoma
cell lines with polyclonal rabbit anti-FABP7 Ab. Small bars represent SD.
LOH, loss of heterozygosity; R, retention of alleles; þ , IHC stained; , IHC
shows not stained; N/A, not available for analysis.
Table 2C. LOH status in metastatic melanomas
Microsatellite markers
Patients D6S268 D6S1072 D6S262 LOH
1 R R R N
2 LOH LOH LOH Y
3 R LOH LOH Y
4 LOH LOH LOH Y
5 R R R N
6 R R R N
7 R R R N
8 R R R N
9 R R R N
10 LOH LOH LOH Y
11 LOH LOH LOH Y
12 R R R N
13 LOH LOH LOH Y
14 LOH LOH LOH Y
15 LOH LOH LOH Y
16 LOH R R Y
17 LOH R R Y
18 LOH LOH LOH Y
19 LOH LOH LOH Y
20 LOH R R Y
LOH, loss of heterozygosity; R, retention of alleles.
LOH inpatient tumor: N, no; Y, yes.
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DISCUSSION
In this study, we assessed the expression of FABP7 in
melanoma progression assessing different stages of primary
and metastatic melanomas, and normal human skin as a
control. Interestingly, the FABP7 mRNA expression in 69%
primary melanoma tissues and 19% metastatic melanoma
tissues FABP7 mRNA copies was significantly above normal
human skin controls. IHC analysis of paired primary and
metastatic melanomas was confirmed in FABP7 protein.
Our study analysis on a well-defined large cohort of primary
and metastatic melanomas of different AJCC stages
showed that, as melanomas progressed, FABP7 expression
decreased significantly. This observation suggested that
FABP7 expression was highly related to melanoma metastasis
development.
It has been shown recently that tumor expression of FABP7
is correlated with poor survival outcome in patients with
glioblastoma (Liang et al., 2005). We previously showed that
FABP7 is involved in the proliferation and invasion of
melanoma cells (Goto et al., 2006). This suggests that FABP7
may be involved in primary tumor development. In this study,
we have shown that FABP7 does not appear to be involved in
primary tumor progression. No significant changes in
progression for stage I to III primary melanomas were
detected. We show that FABP7 expression in metastases of
melanoma was associated with a significantly lower relapse-
free and poorer overall survival expression. The findings were
similar to the results reported with glioblastoma patients
(Liang et al., 2005). These findings of the gioblastoma and our
study strongly suggest that FABP7 expression in tumors has a
significant role in disease outcome. Interestingly, the loss of
expression may be related to genomic instability of the
chromosome 6q23 region.
The studies showed that LOH on the 6q21–23 region
containing the FABP7 gene is associated with and can
explain to some extent the downregulation or loss of FABP7
expression in metastatic cutaneous melanoma. Deletions and
genomic instability of the long arm of chromosome 6 (6q) are
among the most common chromosomal alterations in
cutaneous melanoma (Millikin et al., 1991; Fujiwara et al.,
1999; Shirasaki et al., 2001; Stark and Hayward, 2007).
Previously, we have shown that LOH is present in the
6q22–23 region in melanoma tissues (Fujiwara et al., 1999).
As cutaneous melanoma progresses, genomic instability
becomes more prominent and LOH becomes more frequent
in specific chromosome regions (Taback et al., 2004).
We found LOH in 50% of metastatic melanomas but none
in primary melanomas. This is a significant genomic
aberration that has not been previously shown in detail for
other LOH analyses on melanomas. LOH was detected in
50% of metastatic melanoma specimens examined, whereas
FABP7 mRNA was detected in only 19% of metastatic
melanomas. Loss of the chromosome region may be a
genomic instability consequence that favors downregulation
and loss of FABP7 expression leading to better prognosis.
Interestingly, in glioblastoma tumors, LOH on chromosome
6q21–23 is frequent and associated with poor prognosis
(Wooten et al., 1999; Wong et al., 2006). Early invasive
melanomas in FABP7 may support melanoma growth. Other
forms of generic regulation of FABP7 could occur. Epigenetic
mechanisms were not likely to be the major cause of
downregulation of FABP7 expression; CpG islands in the
immediate promoter region of the FABP7 gene were not
detectable.
Detection of CTCs are promising prognostic blood
biomarkers for the detection of recurrence or progression of
melanoma (Koyanagi et al., 2005a, b; Mocellin et al., 2006).
We hypothesized that FABP7 may be used to detect CTCs
and subclinical metastasis in blood in early stages of
melanoma. It is known that subclinical distant metastasis
occurs at early stages of melanoma such as in AJCC stage II/III
disease; however, clinical detection (systemic recurrence) is
not evident until after extensive follow-up time beyond the
primary tumor removal (Morton et al., 2006). Identification of
early-stage melanoma cells released from metastatic tumors
may be of clinical utility in identifying these high-risk
melanoma patients who have potential of developing
systemic metastatic disease. It has been shown that the death
rates of patients who have AJCC stage I/II disease after
primary tumor removal within 12 years can range from about
5–50%, depending on the disease status and how early the
disease was detected (Balch et al., 2001; Morton et al., 2006).
Detection of FABP7 biomarker as a CTC surrogate in the blood
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Figure 6. Melanoma cell spiking of PBLs. FABP7 qRT quantification of
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indicates its potential utility for detection of biomarker
subclinical metastasis in early-stage disease, whereas the
value of FABP7 in stage IV disease is unfortunately limited
because of the loss of gene expression in metastatic tumors.
The results of the CTC analysis of FABP7 also support the
findings of FABP7 expression in primary and metastatic
tumors. In addition, the detection of FABP7 in CTCs may be
associated with poor prognosis, and be useful as a predictive
biomarker to identify high-risk patients. We could not assess
the relation between the detection of FABP7 in CTCs and the
prognosis of melanoma patients in this study, because patients
have not been followed up long enough.
In summary, FABP7 expression is significantly decreased
because of LOH on the 6q21–23 region containing FABP7
gene in metastases of melanoma. FABP7 expression in
metastasis of melanoma is associated with a significantly
poor disease outcome. These findings suggest that FABP7
may function as a tumor progression gene of melanoma, and
can be a valuable tumor prognostic biomarker. FABP7 can be
used as a potential diagnostic of early-stage melanoma
systemic CTC spreading in the blood.
MATERIALS AND METHODS
Cell lines, tissues, and blood
Ten human metastatic melanoma cell lines established and
characterized at the John Wayne Cancer Institute (JWCI) were used:
ME-19, ME-25, ME-26, ME-27, ME-28, ME-29, ME-30, ME-31,
ME-32, and ME-33. All cell lines were grown in GIBCO RPMI 1640
(Invitrogen, Carlsbad, CA) medium supplemented with 10% heat-
inactivated fetal bovine serum. Cells were cultured at 37 1C in a
humidified atmosphere containing 5% CO2, as previously described
(Mori et al., 2005).
Paraffin-embedded archival tissue (PEAT) specimens from AJCC
melanoma patients were used for comparative analysis: 30 stage I
primary melanomas, 25 stage II patients, and 32 stage III patients,
and metastatic melanomas from 32 stage III patients, and 36 stage IV
patients. PEAT specimens (n¼ 74) of 37 paired primary and
metastatic melanomas were used for IHC analysis. Thirteen PEAT
specimens of normal skin from sun-exposed anatomical sites of these
patients were used as controls. All PEAT specimens were histo-
pathology verified by a pathologist.
Blood specimens were obtained preoperatively from 134 patients
who underwent surgical treatment of AJCC stage I/II (N¼ 72), stage
III (N¼ 34), and stage IV (N¼ 28) melanoma. Blood was collected in
2 4.5ml sodium citrate tubes, and the first several ml were
discarded to eliminate skin-plug contamination. Nucleated cells
from patient blood were processed to RNA, quantified, and assessed
for CTCs by qRT as previously described (Koyanagi et al., 2005b). All
blood specimens were then coded by a computer-generated number
so that the qRT–PCR study could be conducted in a blinded manner.
Peripheral blood lymphocytes from 93 healthy normal donors served
as controls. Total cells in the blood were collected by using
Purescript RBC lysis solution (Gentra, Minneapolis, MN) following
the manufacturer’s instructions. Informed human subject were
approved by Saint John’s Health Center/JWCI institutional review
board, and the approval of the medical ethics committee of the
Shinshu U. School of Medicine was obtained for all patient
specimens. The study was conducted according to the Declaration
of Helsinki Principles and all patients provided signed, written
informed consent to participate in this study.
RNA isolation, primers, and probes
Total RNA was extracted from cell lines and PBL specimens using
Tri-Reagent (Molecular Research Center Inc., Cincinnati, OH), as
previously described (Takeuchi et al., 2004; Koyanagi et al., 2005b).
For RNA extraction from tissue specimens, 5 10 mm-thick sections
were cut from each PEAT block with a sterile microtome blade and
placed in sterile microcentrifuge tubes (Eppendorf, Westbury, NY).
After deparaffinization, specimens were treated with a proteinase K
digestion buffer for 3 hours before RNA extraction, as previously
described (Goto et al., 2006). Total RNA was extracted, isolated, and
purified using a modified RNAWiz (Applied Biosystems, Foster City,
CA) phenol–chloroform extraction method, as previously described
(Goto et al., 2006; Kim et al., 2006). RNA from cell lines and
specimens was quantified and assessed for purity by UV spectro-
photometry and a RiboGreen detection assay (Invitrogen), as
previously described (Koyanagi et al., 2005b).
The development and optimization strategy for primer and probe
sequences of the qRT assay was previously described elsewhere
(Takeuchi et al., 2004). Fluorescence resonance energy transfer
probe sequences for the FABP7 PCR product were designed to
enhance the specificity of the assay. Specific primers were designed
to sequence at least one exon–exon region. The FABP7 primer
sequences were as follows: 50-AAGTCTGTTGTTAGCCTGGA-30
(forward); 50-AGGGTCATAACCATTTTGC-30 (reverse); 50-FAM-TAC
AGAAATGGGATGGCAAAGAAA-BHQ-1-30 (fluorescence reso-
nance energy transfer). The glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) primer sequences were as follows: 50-GGGTGTGA
ACCATGAGAAGT-30 (forward); 50-GACTGTGGTCATGAGTCCT-30
(reverse); 50-FAM-CAGCAATGCCTCCTGCACCACCAA-BHQ-1-30
(fluorescence resonance energy transfer). Expression of the house-
keeping gene GAPDH served as an internal reference for mRNA
integrity.
qRT assay
For cell lines and PBL specimens, reverse transcription (RT) reactions
were performed using Moloney murine leukemia virus RT (Promega,
Madison, WI) with oligo-dT primer as previously described
(Koyanagi et al., 2006). Each PCR was subjected to 40 cycles of
denaturation at 95 1C for 60 seconds, annealing at 56 1C for
60 seconds, and extension at 72 1C for 60 seconds for FABP7; and
40 cycles of denaturation at 95 1C for 60 seconds, annealing at 55 1C
for 60 seconds, and extension at 72 1C for 60 seconds for GAPDH.
For PEAT specimens, RT reactions were performed with both oligo-
dT and random hexamers (Takeuchi et al., 2004). The qRT assay was
performed with the iCycler iQ RealTime PCR Detection System (Bio-
Rad Laboratories, Hercules, CA) using 250 ng of total RNA for each
reaction, and the mRNA copy number was calculated.
Each sample was assayed in duplicate with appropriate positive
(melanoma cell line) and negative controls (normal PBLs) and
reagent controls. Specific plasmid controls of FABP7 and GAPDH
were synthesized as described previously (Goto et al., 2006), and
standard curves for each gene were generated with a threshold cycle
of six serial dilutions of plasmid templates (106–101 copies). PCR
efficiency evaluated from the slopes of the curves was between 95
and 100%. The correlation coefficient for all standard curves
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wasX0.99. The product size of FABP7 and GAPDH was confirmed
by gel electrophoresis, and then optimized for assay conditions for
qRT. The cutoff for FABP7 positivity was set at 0.0011 (ratio of
FABP7/GAPDH mRNA copies), a value that exceeded the mean ratio
of the FABP7/GAPDH mRNA copies plus 3 SD above normal human
skin controls.
DNA extraction
Genomic DNA was extracted from melanoma lines and autologous
PBLs, as previously described (Spugnardi et al., 2003). Tissue sections
were cut from 14 primary and 20 PEAT metastases, stained with
hematoxylin and eosin, and microdissected as previously described
(Shinozaki et al., 2004). Normal tissue (normal skin for primary
melanoma and lymph node metastases comparison, and normal
liver for liver metastases comparison) taken from the same slide
was the source of control DNA (Fujimoto et al., 2004). Dissected
tissues were digested with proteinase K overnight at 50 1C, followed
by heat denaturation for 10minutes at 95 1C. Lysates were directly
used as templates for PCR, as previously described (Fujimoto et al.,
2004).
Microsatellite analysis
Loss of heterozygosity (LOH) was assessed using three known
microsatellite markers (D6S268, D6S1702, and D6S262) encom-
passing the FABP7 gene locus at 6q22.31. LOH was assessed as
previously described for microsatellite instability (Fujimoto et al.,
2004). The primer sets were as follows: D6S268, 50-CTAGGTGG
CAGAGCAACATA-30 (forward) and 50-AAAAGGAGGTCATTT
TAATCG-30 (reverse); D6S1702, 50-AAGGAGCCATTTT TGTGC-30
(forward) and 50-TGCCAGCATTTTTTGGA-30 (reverse); D6S262,
50-ATTCTTACTGCTGGAAAACCAT-30 (forward) and 50-GGAGCATA
GTTACCCTTA AAATC-30 (reverse). Forward primers were labeled
with WellRED dye-labeled phosphoramidites (Beckman Coulter Inc.)
as previously described (Fujimoto et al., 2004). The PCR amplifica-
tion was performed in a 10-ml reaction volume with 1-ml template for
40 cycles of 30 seconds at 94 1C, 30 seconds at 56 1C, and 30 seconds
at 72 1C, followed by a 7-minute final extension at 72 1C. PCR
product separation was performed using capillary array electrophor-
esis (CAE CEQ 8000XL; Beckman Coulter Inc., Fullerton, CA). Peak
signal intensity and relative size were generated by fragment analysis
system software (Beckman Coulter Inc.) (Fujimoto et al., 2004).
Tumors were scored as LOH when one allele showed 50% or more
reduction of peak intensity for tumor DNA when compared with the
corresponding allele identified in the control DNA, or retention of
alleles (R) when the allele showed less than 50% reduction of peak
intensity for tumor DNA as previously described (Fujimoto et al.,
2004). Autologous patients’ PBLs served as normal controls for
respective melanoma cell line analyses.
IHC staining
Immunohistochemical staining of melanoma cell lines with poly-
clonal rabbit anti-FABP7 antibodies was performed as previously
described (Goto et al., 2006). All IHC staining was assessed by two
independent dermatopathologists.
Statistical analysis
Receiver operating characteristic curve analyses was conducted to
evaluate the diagnostic accuracy of FABP7, using primary melano-
ma/normal skin tissue as a binary outcome and the FABP7 value as
possible cutoff points for computation of sensitivity and specificity.
Area under the curve was computed to measure the predictive
power. A Wilcoxon rank sum test was used to assess differences in
FABP7 mRNA expression between primary melanomas and normal
skin, between primary melanomas and metastatic melanomas, and
between blood specimens from melanoma patients and healthy
volunteers. Fisher’s exact test was used to assess the frequency of
FABP7 expression in primary versus metastatic melanomas, the
frequency of LOH in primary versus metastatic melanomas, and the
association between the expression of FABP7 and AJCC stage in CTC
blood. McNemar’s test was used to compare the frequency of FABP7
expression in the paired samples of primary and metastatic
melanomas. Relapse-free survival and overall survival from surgery
were used for outcome measurement. Survival curves were
generated using the Kaplan–Meier method. Univariate analysis of
relapse-free survival and overall survival for FABP7 detection and
clinicopathologic factors (gender, age, primary site, pT stage, Clark
level, N classification, M classification, and AJCC stage) were carried
out using the log-rank test. Cox proportional hazard model was
developed for multivariate analysis to examine the association of
FABP7 detection with relapse-free survival and overall survival
controlling for clinicopathologic variables. A stepwise procedure
was used for prognostic variable selection. SAS software (SAS
Institute, Cary, NC) was used for statistical analysis and all tests were
two-sided with a significance level of Po0.05.
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